Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Virax Biolabs Group Ltd. Class A ( (VRAX) ) has issued an announcement.
Virax Biolabs Group Limited, a London-based immunology-focused biotech listed on Nasdaq, is concentrating its business around ViraxImmune, an in-development T cell immune-profiling assay designed to identify immune dysfunction in post-acute infection syndromes such as Long COVID, post-treatment Lyme disease and ME/CFS. The company’s U.S. strategy is to first commercialize ViraxImmune via a Laboratory Developed Test pathway, with broader in vitro diagnostic development and a staged coding and reimbursement approach to follow over time.
On April 14, 2026, Virax published a shareholder letter from CEO James Foster and an updated Q2 2026 investor presentation outlining near-term milestones over the next 90 to 180 days, including a key PAIS data readout, continued U.S. clinical validation planning with Emory University and progression toward a U.S. market-entry path. Management highlighted recent operational progress—full recruitment in U.K. PAIS studies, completion of an FDA pre-submission meeting and ISO 13485/9001 certifications—and emphasized that Virax remains debt-free with about $6.4 million in cash as of March 31, 2026, arguing that the company’s approximate $2.6 million market capitalization significantly undervalues its balance sheet strength and advancing clinical and commercial programs.
The most recent analyst rating on (VRAX) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Virax Biolabs Group Ltd. Class A stock, see the VRAX Stock Forecast page.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited is an innovative biotechnology company focused on immunology research, specifically the detection of immune responses and diagnosis of viral diseases. The company is developing T cell-based testing technologies to create an immune-profiling platform aimed at post-acute infection syndromes, including Long COVID, post-treatment Lyme disease and other chronic conditions linked to immune dysregulation, with an initial emphasis on the U.S. diagnostics market.
Average Trading Volume: 12,329,375
Technical Sentiment Signal: Sell
Current Market Cap: $772.8K
Find detailed analytics on VRAX stock on TipRanks’ Stock Analysis page.